Gujarat Kidney & Super Speciality IPO Review
Gujarat Kidney & Super Speciality IPO has been reviewed by 10 analysts, and the overall consensus is May Apply — carrying a score of 58. Out of the 10 analysts who have covered this IPO, 5 recommend subscribing while 5 advise caution or avoidance — reflecting a mixed view from the analyst community.
The issue is priced in the band of ₹108 to 114 per share, with a minimum application size of 128 shares (minimum investment of approximately ₹13,824 at the upper band). Subscription ran from 22 Dec 2025 to 24 Dec 2025. The issue size is ₹251 crore, entirely a fresh issue. As of now, the grey market premium (GMP) for Gujarat Kidney & Super Speciality IPO is quoting at ₹55 (10%%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Analyst verdict & score
One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated
Higher consensus indicates broader analyst agreement.
Detailed review
What the analyst reports say, grouped by the question you're likely asking.
General review
Listing gains
Short-term strategy
Long-term strategy
How this is written: an AI-assisted summary of the 13 analyst reports listed below. It reports their views; IPO Guru does not make buy or sell recommendations.
Analyst reviews
Ordered by each analyst's track record over the past year; analysts still building one are listed last.
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Gujarat Kidney & Super Speciality IPO?
The analyst consensus for Gujarat Kidney & Super Speciality IPO tracked on this page is May Apply, with a score of 58/100. Out of 10 analysts who have reviewed this IPO, 5 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of 58 mean for Gujarat Kidney & Super Speciality IPO?
The score of 58 is an aggregate of all analyst ratings tracked for Gujarat Kidney & Super Speciality IPO. A score in this range reflects mixed views — some analysts are positive while others are cautious. Read the individual analyst verdicts above for more context.
What was the actual listing price of Gujarat Kidney & Super Speciality IPO?
Gujarat Kidney & Super Speciality IPO listed on December 30, 2025 at ₹120, against the issue price of ₹114 — a gain of +5.26% (₹6 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Gujarat Kidney & Super Speciality IPO?
Gujarat Kidney & Super Speciality IPO was priced at ₹108 to 114 per share. The minimum lot size is 128 shares, making the minimum investment approximately ₹13,824 at the upper end of the price band. Subscription ran from 22 Dec 2025 to 24 Dec 2025.
Explore Gujarat Kidney & Super Speciality IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
